‘Human foie gras’ whets appetite of drugs giants

Paris (AFP) – As obesity expands waistlines in the Western world, a silent killer linked to the condition nicknamed “human foie gras” is spurring a potential bonanza worth billions for drugs giants.The disease, formally known as non-alcoholic steatohepatitis (NASH), is caused by a buildup of fat in the liver. It is already the leading ailment cited in requests for liver transplants in the United States, Cecile Rabian of France’s Gilead laboratory told AFP.”We imagine that this will also be the case in Europe very soon,” she added.The GlobalData research group estimates that NASH could underpin a market worth more than $25 billion (22 billion euros) by 2026.And the market should grow by a healthy 45 percent each year in the initial phases of the rollout of drugs to counter the disease, GlobalData says — with the main customer base in the United States, western Europe and Japan.

Source: ‘Human foie gras’ whets appetite of drugs giants

Advertisements
Categories: Uncategorized

Post navigation

Comments are closed.

Create a free website or blog at WordPress.com.

%d bloggers like this: